PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)
M. C. Pirosa,L. Orsucci,P. Feugier,M. Tani,Hervé Ghesquieres,G. Musuraca,L. Baldini,F. Merli,B. De Renzis,E. Gyan,G. Gini,D. Marino,R. Gressin,F. Morschhauser,F. Palombi,F. Cavallo,A. Conconi,S. Le Gouill,Hervé Tilly,M. Zanni,M. G. Cabras,E. Capochiani,C. Califano,A. L. Molinari,A. Pulsoni,F. Angrilli,G. Cartron,O. Casasnovas,L. Devizzi,C. Haioun,R. Houot,A. M. Liberati,U. Occhini,M. Merli,G. Pietrantuono,F. Re,M. Spina,F. Esposito,F. Bertoni,D. Rossi,N. Ielmini,S. Luminari,F. Cavalli,E. Zucca,A. Stathis,C. Thieblemont Hematological Oncology（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper